| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/09/2003 | EP1299086A1 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 04/09/2003 | EP1299085A2 Improved liposomal camptothecins and uses thereof |
| 04/09/2003 | EP1299084A2 Liposomal antineoplastic drugs and uses thereof |
| 04/09/2003 | EP1299081A1 Use of oligosaccharides to stimulate beta-endorphin production |
| 04/09/2003 | EP1299032A1 DNA encoding human serine protease D-G |
| 04/09/2003 | EP1299011A2 Composition for the treatment of migraine |
| 04/09/2003 | EP1140055B1 Use of a 5ht 2a? and 5ht 2a/c? receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 04/09/2003 | EP1109567A4 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system |
| 04/09/2003 | EP0963197A4 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 04/09/2003 | EP0946165B1 Integrin antagonists |
| 04/09/2003 | EP0928200B1 Therapeutic combinations of rar antagonists and rxr agonists |
| 04/09/2003 | EP0831726B1 Health food product |
| 04/09/2003 | EP0827396B1 Production scale method of forming microparticles |
| 04/09/2003 | EP0723455B1 Method of inhibiting phagocytosis |
| 04/09/2003 | CN1409722A Antagonists of BMP and TGF beta signalling pathway |
| 04/09/2003 | CN1409712A Pyrrolo [2,3-d] pyrimidine compounds |
| 04/09/2003 | CN1409711A Fused naphthalene dinitrogen compound useful as HIV reverse transcriptase inhibitors |
| 04/09/2003 | CN1409708A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitor |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1409635A Treatment of systemic lupus erythematosus with dehydroepiandrosterone |
| 04/09/2003 | CN1409634A Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| 04/09/2003 | CN1409633A Combinations of(S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxion[2,3-e]indol-8-one and neuroleptics |
| 04/09/2003 | CN1409626A Catechol oximes and their use in cosmetic and dermatological preparations |
| 04/09/2003 | CN1409605A Method for increasing pet activity |
| 04/09/2003 | CN1409587A Method for forming holes, using flexible connection board formed thereof and its producing method |
| 04/09/2003 | CN1408437A Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method |
| 04/09/2003 | CN1408435A Method for medicinal matter for nose |
| 04/09/2003 | CN1105114C Sulfonyl divalent aryl alpha-hydroxy-iso-hydroximic acid compounds |
| 04/09/2003 | CN1104910C Production of analgesic synergy by co-administration of sub-analtesic doses of mu-opioid. agonist and kappa-2 opoiid agonist |
| 04/09/2003 | CN1104909C Composition for prevention and treatment of HIV-1 infection comprising at least two different HIV-1 reverse transcriptase inhibitors |
| 04/09/2003 | CN1104908C Improved vision through photodynamic therapy of eye |
| 04/09/2003 | CN1104896C RAR-gamma antagonist ligand or RAR-alpha agonist ligand as apoptosis inhibitor |
| 04/09/2003 | CN1104855C Composition and its use as food supplement or for lowering lipids in serum |
| 04/08/2003 | WO2004028529A1 Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person |
| 04/08/2003 | US6545097 Biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks connected by a seed polymer |
| 04/08/2003 | US6545057 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 04/08/2003 | US6545049 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof |
| 04/08/2003 | US6545036 Potassium channel blockers; neuroprotectants, glaucoma, n-benzoyl indole compounds with 3-acylureamethyl group |
| 04/08/2003 | US6545034 Effective to reduce the viability and/or to sensitize the cancer to an anti-cancer agent. |
| 04/08/2003 | US6545030 1-heterocycle substituted diarylamines |
| 04/08/2003 | US6545021 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| 04/08/2003 | US6545007 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 04/08/2003 | US6545001 Antiviral nucleoside analogues |
| 04/08/2003 | US6544998 Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| 04/08/2003 | US6544988 Tyrosine kinase inhibitors |
| 04/08/2003 | US6544982 3-aryl-5-aminoisoxazole derivatives |
| 04/08/2003 | US6544979 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents |
| 04/08/2003 | US6544970 Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative |
| 04/08/2003 | US6544961 Especially for treatment of infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. |
| 04/08/2003 | US6544957 Histone acetylase inhibitor |
| 04/08/2003 | US6544955 Method of sensitizing tumor cells with adenovirus E1A |
| 04/08/2003 | US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine |
| 04/08/2003 | US6544740 Measuring protease; calibration; insertion of enbryos |
| 04/08/2003 | US6544556 Prevents gastrointestinal side effects |
| 04/08/2003 | US6544555 Dosage forms; variations in rrelease profile |
| 04/08/2003 | US6544550 Medicaments for gastrointestinal disorders |
| 04/08/2003 | US6544545 Providing needle-less device comprising a barrel member and a plunger, contacting first end of the barrel member to the patient's skin; depressing the plunger, thereby forcing medicament through the skin, to thereby administer medicament |
| 04/08/2003 | US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 04/08/2003 | US6544541 Devices and compounds for treating arterial restenosis |
| 04/08/2003 | US6544516 Treating with anitbodies for bactericidal activity against enterococci |
| 04/08/2003 | US6544193 Noninvasive measurement of chemical substances |
| 04/08/2003 | CA2163524C Assay and reagents for identifying anti-proliferative agents |
| 04/08/2003 | CA2061907C Treatment of ocular hypertension with a synergistic combination |
| 04/08/2003 | CA2053216C Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| 04/08/2003 | CA2023810C Pharmaceutical composition |
| 04/03/2003 | WO2003027637A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 04/03/2003 | WO2003027316A2 Methods of using 33751, a human potassium channel family member |
| 04/03/2003 | WO2003027313A2 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| 04/03/2003 | WO2003027287A1 Kidney-specific urate transporter and gene thereof |
| 04/03/2003 | WO2003027285A1 Dna sequences for human angiogenesis genes |
| 04/03/2003 | WO2003027284A1 Bone metablic disease markers and utilization thereof |
| 04/03/2003 | WO2003027282A1 Adamts-15, -16, -17, -18 and -19 |
| 04/03/2003 | WO2003027275A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 04/03/2003 | WO2003027263A2 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | WO2003027255A2 Anti-fusion assay |
| 04/03/2003 | WO2003027233A2 Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
| 04/03/2003 | WO2003027228A2 Receptors and membrane-associated proteins |
| 04/03/2003 | WO2003027143A2 Gene and protein relating to hepatocellular carcinoma |
| 04/03/2003 | WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| 04/03/2003 | WO2003027113A1 1,6-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | WO2003027112A1 1, 8-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | WO2003027091A1 Pyrane derivatives as both ace- and nep- inhibitors |
| 04/03/2003 | WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | WO2003026743A2 Opioid formulations having reduced potential for abuse |
| 04/03/2003 | WO2003026714A1 Porous ceramic composite bone grafts |
| 04/03/2003 | WO2003026699A1 Medicinal compositions promoting drug absorption |
| 04/03/2003 | WO2003026696A1 Method of controlling proliferation of cancer cells and cell death |
| 04/03/2003 | WO2003026684A1 Modulation of physiological processes and agents useful for same |
| 04/03/2003 | WO2003026674A1 Coadministration of transport protein with conjugated cobalamin to deliver agents |
| 04/03/2003 | WO2003026672A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 04/03/2003 | WO2003026669A1 Monobactam antibacterial compounds and methods of use thereof |
| 04/03/2003 | WO2003026649A1 Methods of increasing endogenous testosterone levels |
| 04/03/2003 | WO2003026644A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 04/03/2003 | WO2003026643A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| 04/03/2003 | WO2003026635A2 Improved method of treating the syndrome of type 2 diabetes in humans |
| 04/03/2003 | WO2003026632A2 Substituted phenol compounds useful for anesthesia and sedation |
| 04/03/2003 | WO2003026611A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 04/03/2003 | WO2003026610A2 Process for the preparation of fast dissolving dosage form |
| 04/03/2003 | WO2003026591A2 Modification of feeding behavior |
| 04/03/2003 | WO2003026589A2 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |